Navigation Links
HCA Reports First Quarter 2009 Results
Date:4/27/2009

First Quarter (Dollars in millions) 2009 2008 ---- ---- Amount Ratio Amount Ratio ------ ----- ------ ----- Revenues $7,431 100.0% $7,127 100.0% Salaries and benefits 2,923 39.3 2,839 39.8 Supplies 1,210 16.3 1,173 16.5 Other operating expenses 1,102 14.8 1,114 15.5 Provision for doubtful accounts 807 10.9 888 12.5 Equity in earnings of affiliates (68) (0.9) (67) (0.9) Depreciation and amortization 353 4.8 357 5.1 Interest expense 471 6.3 530 7.4 Losses (gains) on sales of facilities 5 0.1 (51) (0.7) Impairment of long-lived assets 9 0.1 - - --- --- --- --- 6,812 91.7 6,783 95.2 ----- ---- ----- ---- Income before income taxes 619 8.3 344 4.8 Provision for income taxes 187 2.5 119 1.6 --- --- --- --- Net income 432 5.8 225 3.2 Net income attributable to noncontrolling interests 72 1.0 55 0.8 -- --- -- --- Net income attributable to HCA Inc $ 360 4.8 $ 170 2.4
'/>"/>
SOURCE HCA Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
2. Neovasc Inc. Reports Year 2008 Financial Results
3. NBTY Reports Second Quarter Results
4. Statement from USPA Exec. Dir. on News Reports of Florida Pharmacy Admission of Error in the Medicine Dispensed to the Horses Who Died on Sunday
5. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
6. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
7. NeoGenomics, Inc. Reports First Quarter 2009 Financial Results
8. Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results
9. CuraGen Reports First Quarter 2009 Financial Results
10. NuVasive Reports First Quarter 2009 Financial Results
11. Torchmark Corporation Reports First Quarter 2009 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)..., Benton Communications a...iness growth system for retailers struggling to ma... (PRWEB) November 26, 2009 -- Flu fears is the ty...es to the emergency room, according to Dr. David B...wly released business growth system – The R...
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBar...ion,slargestmedicalcliniconDec.9-10,whenKansasCity...suredpeople. ,, "Thisfreecliniceventhasthepoten...odaysinsteadofjustoneandbeheldonweekdaysinsteadofo...sCityFreeHealthClinicandpresidentoftheNationalAsso...
(Date:11/25/2009)...,, TORONTO,Nov.25/PRNewswire/-SentinelleMedi...ancedvisualizationsoftwarelaunchesasuiteofnewleadi...gingsoftwareplatformatthisyear,sRadiologicalSociet...-Dec.5,2009(Booth5800,HallA).Theapplicationslevera...sspecializedMRIimagingcoilsandsupportmultipleimagi...
(Date:11/25/2009)...,, LOSANGELES,Nov.25/PRNewswire-USNewswire/-...lectionstodetermineexecutiveleadershipfor2010. ,...rswithspecialtiesinpublicpolicy,law,finance,govern...urship.TheBoardalsocomesfromawiderangeofpersonalba...dwomen,somelivingwithHIVthemselves,andrepresenting...
(Date:11/25/2009)..., Long-term survivors of testicular cancer who we...ore severe side effects, including neurological si...o were not treated with chemotherapy, according to...Journal of the National Cancer Institute . , Mar...Haukeland University Hospital, in Bergen, Norway, ...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...ookdale Senior Living Inc. (NYSE: BKD ) announce... 2009 financial results after the market closes on...eduled a conference call to discuss the results on...utside of the U.S.) ten minutes prior to the sched...
...e American Academy of Dermatology (Academy) today ...d Drug Administration,s (FDA) announcement that a ...inum toxin products and a medication guide will be...nd severe underarm sweating (hyperhidrosis). ...
...erage of International Scholarly Journals, Web of ...ting to Influenza Epidemics, Affording Knowledge a...u Outbreak , , PHILADELPHIA and LONDON, April 30 ...nces from around the globe in all fields of schola...
... Texas, April 30 The battle for beauty now goes w...has received FDA clearance and is expected to begi...next sixty days. The arrival of Dysport(TM) into t... to be promoting one over the other, and as altern...
...use of drugs to encourage red blood cell formation...ients with anemia increases the risk of death and ...a new study in CMAJ . , While the relative inc... people. , "These findings suggest that erythropo...
...or, Inc. (Nasdaq: BLUD ), a global leader in pro... blood transfusion industry, today announced that ...and Merrill Lynch 2009 Health Care Conference in N.... Eastern time. Access to the presentation will be...
Other Medicine News:Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products 2Health News:Thomson Reuters Web of Science(R) Provides Insights Into More than a Century of Influenza Research for Today's Health Professionals 2Health News:Thomson Reuters Web of Science(R) Provides Insights Into More than a Century of Influenza Research for Today's Health Professionals 3Health News:Thomson Reuters Web of Science(R) Provides Insights Into More than a Century of Influenza Research for Today's Health Professionals 4Health News:New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble 2Health News:New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble 3Health News:Drugs to combat anemia in cancer patients increase risk of death 2
(Date:11/25/2009)...therlandsandJOHANNESBURG,November25/PRNewswire/--,...overyannouncedtoday,thattheyhavesignedacollaborati... , Pyxis,sworldclasscomputationalchemistryand...ervicedivisiontoprovidemedicinaland,syntheticchemi...nationalclientnetwork.iThembaPharmaceuticalsandPyx...
(Date:11/24/2009)...Nov.24/PRNewswire/-- ,, WHAT:RomHoubens,aBelgia...toaccident,wasactuallyfullyconsciousandawakeduring...nt.TheDynaVoxEyeMaxwasfeaturedinthesegmenttoillust...nscanunlockcommunication. ,, WHEN:GoodMorningAm...w.dynavoxtech.com ,, WHO:RomHoubenswasaneng...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--AnadysPharmaceuticals,...atthe21stAnnualPiperJaffrayHealthcareConferenceonT...econferenceisbeingheldatTheNewYorkPalaceHotel.Stev...Anadys,willprovideanoverviewofAnadysanditsclinical...oratepresentationwillbesimultaneouslywebcastandcan...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 1Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 2Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 3Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 4Angiotech Pharmaceuticals announces the commercial launch of the Option 28TM 29 Inferior Vena Cava Filter in the United States 13637 5WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 1WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 2WorldHeart Receives US Clinical Study Approval for the Levacor 28TM 29 VAD 4876 3Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 1Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease 4874 3
Sugita Aneurysm Clip 45 Angled (L)
Sugita Aneurysm Clip Slightly Cvd. (L)
Sugita Aneurysm Clip Slightly Cvd.
Sugita Aneurysm Clip Slightly Bent
Medicine Products: